Alberts, B., Johnson, A., Lewis, J., Raff, M., Roberts, K., Walter, P. (2008). Molecular Biology of THE CELL. New York: Garland Science Taylor & Frabscis Group.
Gentier, R.J., Leeuwen, van F.W. (2015). Misframed ubiquitin and impaired protein quality control: an early event in Alzheimer´s disease. Frontiers in Molecular Neuroscience. DOI: https://doi.org/10.3389/fnmol.2015.00047.
Gong, C.X., Iqbal, K. (2008). Hyperphosphorylation of Microtubule-Associated Protein Tau: A Promising Therapeutic Target for Alzheimer Disease. Current Medicinal Chemistry, 15 (23), 2321-2328.
Hendel, A., Fine, E.J., Bao, G., Porteus, M.H. (2015). Quantifying On and Off-Target Genome Editing. Trends Biotechnology, 33(2). DOI: 10.1016/j.tibtech.2014.12.001.
Horvath, P., Barrangou, R. (2010). CRISPR/Cas, the immune system of bacteria and archaea. Science, 327 (5962), 167-70. DOI: 10.1126/science.1179555.
Huang, H., Jiang, Z. (2009). Accumulated Amyloid-β Peptide and Hyperphosphorylated Tau Protein: Relationship and Links in Alzheimer’s Disease. Journal of Alzheimer’s Disease 16 (2009) 15–27. DOI: 10.3233/JAD-2009-0960
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J.A., Charpentier, E. (2012). A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity. Science, 337(6096), 816-821. DOI: 10.1126/science.1225829.
Komor, A.C., Kim, Y.B., Packer, M.S., Zuris, J.A. & Liu, D.R. (2016). Programmable editing of target base in genomic DNA without double-stranded DNA cleavage. Nature, 533, 420-424. DOI: 10.1038/nature17946.
Moreno, A.M., Mali, P. (2017). Therapeutic genome engeneering via CRISPR-Cas systems. WIREs Systems biology and Medicine, 1380. DOI: 10.1002/wsbm.1380.
O´Brien, R.J., Wong, P.C. (2011). Amyloid Precursor Protein Processing and Alzheimer´s Disease. Annual Review of Neuroscience, 34, 185-204. DOI: 10.1146/annurev-neuro-061010-113613
Paquet, D., Kwart, D., Chen, A., Sproul, A., Jacob, S., Teo, S., Olsen, K.M., Gregg, A., Noggle, S., Tessier-Lavigne, M. (2016). Efficient introduction of specific homozygous and heterozygous mutations using CRISPR/Cas9. Nature,533, 125–129. DOI:10.1038/nature17664.
Tschaharganeh, D.F., Lowe, S.W., Garippa, R.J., Livshits, G. (2016). Using CRISPR/Cas to study gene function and model disease in vivo. The Febs Journal, 283(17), 3194-3203. DOI: 10.1111/febs.13750.
Ullah, N., Khan, N.M., Ullah, W. (2015). Alzheimer’s disease, Epidemiology, causes, diagnosis and novel treatments: A review. International Journal of Basic Medical Sciences and Pharmacy, 5(2), 2049-4963.
U.S. National Library of Medicine (2017). APP Gene. Amyloid Precursor Protein. Genetic home reference.https://ghr.nlm.nih.gov/gene/APP#conditions geraadpleegd op 18 januari 2018.
Weggen, S., Beher, D. (2012). Molecular consequences of amyloid precursor protein and presenilin mutations causing autosomal-dominant Alzheimer's disease. Alzheimer's Research & Therapy, 4(9). DOI: 10.1186/alzrt107.